This disclosure summarizes the most important risks associated with medications you may be prescribed through Van Peptides. It is for informational purposes and does not replace personalized medical advice from your provider. Always inform your provider of all medications, supplements, and medical conditions before starting any treatment. Individual responses to medication vary. Report any adverse effects promptly and follow your provider's guidance. In a medical emergency, call 911.
GLP-1 medications
Semaglutide (injectable)
Common side effects: nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, fatigue, headache, and injection-site reactions.
Serious risks: pancreatitis, gallbladder problems (gallstones, cholecystitis), acute kidney injury (from dehydration), intestinal obstruction, thyroid C-cell tumors (boxed warning based on animal studies), severe hypoglycemia when combined with insulin or sulfonylureas, and severe allergic reactions.
Contraindications: personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), pregnancy and breastfeeding, severe gastrointestinal disease, and type 1 diabetes.
Drug interactions: insulin and sulfonylureas (increased hypoglycemia risk), oral contraceptives (reduced absorption), and oral medications generally (delayed absorption due to slowed gastric emptying).
Tirzepatide (injectable)
Common side effects: nausea, diarrhea, decreased appetite, vomiting, dyspepsia, constipation, abdominal pain, fatigue, headache, hair loss, mild heart-rate increase, and injection-site reactions.
Serious risks: thyroid C-cell tumors (boxed warning), pancreatitis, gallbladder disease, acute kidney injury, severe hypoglycemia, diabetic retinopathy worsening, tachycardia, bowel obstruction, and severe allergic reactions including anaphylaxis.
Contraindications: personal or family history of MTC or MEN2, pregnancy and breastfeeding, severe gastrointestinal disease, and type 1 diabetes. History of pancreatitis requires clinical judgment.
Drug interactions: insulin and sulfonylureas, oral medications (delayed absorption), warfarin (monitor INR), and oral contraceptives.
Semaglutide microdose (sublingual)
Common side effects: generally milder than full-dose injectable semaglutide due to lower dosing. Possible mild nausea, decreased appetite, occasional headache, fatigue, mild GI upset, and transient taste changes from sublingual administration.
Serious risks: the same class-level risks of GLP-1 receptor agonists still apply, including pancreatitis, gallbladder problems, acute kidney injury (from dehydration), thyroid C-cell tumors (boxed warning based on animal studies), severe hypoglycemia when combined with insulin or sulfonylureas, and severe allergic reactions.
Contraindications: personal or family history of MTC or MEN2, pregnancy and breastfeeding, severe gastrointestinal disease, type 1 diabetes, and known hypersensitivity to semaglutide or any excipient in the sublingual formulation.
Drug interactions: insulin and sulfonylureas (increased hypoglycemia risk), oral contraceptives (reduced absorption), and oral medications generally (delayed absorption due to slowed gastric emptying).
Important note: sublingual semaglutide is a compounded formulation. It is not FDA-approved and has not been evaluated by the FDA for safety or efficacy at this route of administration.
Tirzepatide microdose (sublingual)
Common side effects: generally milder than full-dose injectable tirzepatide due to lower dosing. Possible mild nausea, decreased appetite, occasional dyspepsia or diarrhea, fatigue, headache, and transient taste changes from sublingual administration.
Serious risks: the same class-level risks of dual GLP-1/GIP receptor agonists still apply, including thyroid C-cell tumors (boxed warning), pancreatitis, gallbladder disease, acute kidney injury, severe hypoglycemia, diabetic retinopathy worsening, tachycardia, bowel obstruction, and severe allergic reactions including anaphylaxis.
Contraindications: personal or family history of MTC or MEN2, pregnancy and breastfeeding, severe gastrointestinal disease, type 1 diabetes, and known hypersensitivity to tirzepatide or any excipient in the sublingual formulation. History of pancreatitis requires clinical judgment.
Drug interactions: insulin and sulfonylureas, oral medications (delayed absorption), warfarin (monitor INR), and oral contraceptives.
Important note: sublingual tirzepatide is a compounded formulation. It is not FDA-approved and has not been evaluated by the FDA for safety or efficacy at this route of administration.
Wellness peptides
Sermorelin
Common side effects: injection-site irritation, headache, flushing, dizziness, nausea, rash, sleepiness, taste changes, and restlessness.
Serious risks: severe allergic reaction or anaphylaxis, cancer risk (growth hormone and IGF-1 stimulation may accelerate tumor growth), and worsened insulin resistance.
Contraindications: active cancer or recent cancer diagnosis (requires oncologist clearance), pregnancy and breastfeeding, known allergy to sermorelin, untreated hypothyroidism, and moderate to severe liver or kidney disease.
Drug interactions: corticosteroids (reduce effectiveness), oral estrogens, insulin and sulfonylureas, somatostatin analogs, levothyroxine, aspirin, and certain beta blockers.
PT-141 (bremelanotide)
Common side effects: nausea, flushing, headache, injection-site reactions, transient blood-pressure elevation, and darkening of skin (focal hyperpigmentation) with repeated use.
Serious risks: significant transient blood-pressure elevation, severe nausea, and hypersensitivity reactions. Not appropriate for patients with uncontrolled hypertension or known cardiovascular disease.
Contraindications: uncontrolled hypertension, known cardiovascular disease, pregnancy and breastfeeding, and known hypersensitivity to bremelanotide.
Drug interactions: other medications that affect blood pressure, and oral medications (delayed absorption).
Energy and wellness injections
NAD+ injection
Common side effects: nausea, flushing, headache, fatigue, mild chest tightness (resolves by slowing infusion), injection-site reactions, dizziness, digestive discomfort, muscle cramps, and sweating.
Serious risks: allergic reaction or anaphylaxis, rapid heart rate, chest pain, severe vein inflammation (IV administration), elevated inflammation markers, glucose intolerance or liver-toxicity signals with long-term use, and fainting.
Contraindications: known hypersensitivity to NAD+ or niacinamide, active cancer, uncontrolled hypertension, congestive heart failure, severe liver or kidney disease, active infections, and pregnancy and breastfeeding.
Drug interactions: mitochondria-affecting medications (metformin, statins, chemotherapy agents), glutathione and alpha-lipoic acid (when combined in infusions), and antidiabetic medications.
Glutathione injection
Common side effects: nausea, headache, injection-site pain, mild allergic reactions (rash, itching), transient breathing discomfort (especially in asthma patients), diarrhea, and abdominal cramping.
Serious risks: endotoxin-related reactions (fever, chills, low blood pressure, difficulty breathing), liver injury, anaphylaxis, potential thyroid dysfunction, kidney dysfunction, cardiovascular effects (blood-pressure drop, irregular heart rhythms), and altered skin photoprotection increasing UV-related skin-damage risk.
Contraindications: known allergy to glutathione, asthma or breathing disorders (bronchospasm risk), liver or kidney disease, immune compromise, and pregnancy and breastfeeding.
Drug interactions: NAD+ and alpha-lipoic acid (overlapping effects in combination infusions) and chemotherapy agents (discuss with oncologist).
MIC-B12 injection (methionine, inositol, choline + vitamin B12)
Common side effects: mild injection-site reactions (redness, soreness, bruising), transient warmth or flushing, mild nausea or upset stomach, headache, change in urine odor (from methionine and B12), and a temporary energy boost or insomnia if injected late in the day.
Serious risks: allergic reaction or anaphylaxis (rare, more often linked to cobalt or preservative sensitivity), low potassium with high-dose B12 in susceptible patients, exacerbation of pre-existing kidney or liver disease, and theoretical worsening of homocysteine-related cardiovascular conditions in patients with untreated B-vitamin metabolism disorders. Sterile injection technique is essential to avoid local infection.
Contraindications: known allergy to methionine, inositol, choline, cobalt, or vitamin B12, Leber's hereditary optic neuropathy, polycythemia vera, severe liver or kidney disease, pregnancy and breastfeeding (only under provider supervision), and active infection at injection sites.
Drug interactions: levodopa (B12 may alter response), chloramphenicol (may blunt hematologic response to B12), metformin and proton-pump inhibitors (long-term use can lower B12 absorption), and methotrexate or other folate antagonists.
Important note: MIC-B12 is a compounded lipotropic injection used as an adjunct to lifestyle changes. It is not a substitute for medically supervised weight management or treatment of B12 deficiency, and individual responses vary.
Important reminders
- Follow your provider's dosing and administration instructions precisely.
- Do not share medication or use medication prescribed for another person.
- Store medications as directed — some require refrigeration.
- If you are pregnant, planning pregnancy, or breastfeeding, discuss with your provider before starting any medication.
- Report any adverse events to your provider promptly and to the FDA MedWatch program at fda.gov/medwatch.
This disclosure is not exhaustive. Always consult your provider before starting, stopping, or changing any medication.
Van Peptides LLC
Email: hello@vanpeptides.com